CMPS
COMPASS Pathways Plc
$12.28
+$0.46(+3.94%)
46
Overall
60
Value
66
Tech
13
Quality
Market Cap
$1.36B
Volume
3.20M
52W Range
$2.25 - $12.24
Target Price
$21.97
Company Overview
| Mkt Cap | $1.36B | Price | $12.28 |
| Volume | 3.20M | Change | +3.94% |
| P/E Ratio | -8.8 | Open | $12.27 |
| Revenue | -- | Prev Close | $11.81 |
| Net Income | $-155.1M | 52W Range | $2.25 - $12.24 |
| Div Yield | N/A | Target | $21.97 |
| Overall | 46 | Value | 60 |
| Quality | 13 | Technical | 66 |
No chart data available
About COMPASS Pathways Plc
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Sector: Industrials
Industry: Research and Development in Biotechnology
Latest News
H.C. Wainwright Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
Analysts Offer Insights on Healthcare Companies: DarioHealth (DRIO), NeuroOne Medical Technologies (NMTC) and COMPASS Pathways (CMPS)
Brian Anderson•13 days ago
EXE, IP, ESPR, CMPS, TNXP Trending With Analysts
TipRanks Weekend Auto-Generated Newsdesk•17 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CMPS | $12.28 | +3.9% | 3.20M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |